First Patient Advanced Prostate Cancer Treated with Harpoon Therapeutics’ HPN424

First Patient Advanced Prostate Cancer Treated with Harpoon Therapeutics’ HPN424
A Phase 1 clinical trial of Harpoon Therapeutics’ immunotherapy candidate, HPN424 for metastatic castration-resistant prostate cancer (mCRPC), has treated the first patient, according to the company. HPN424 uses the Harpoon’s TriTAC (Tri-specific T cell Activating Construct) platform. This approach is intended to work as an adaptor, connecting the patient’s own immune T-cells with tumor cells. This is possible because TriTAC products target cancer

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *